Treatment Intensification with XTANDI
Loading Map....
Treatment Intensification with XTANDI (enzalutamide) for Patients with Metastatic Castration-sensitive Prostate Cancer (mCSPC) and Nonmetastatic Castration-sensitive Prostate Cancer (nmCSPC) with Biochemical Recurrence at High-risk for Metastasis (High-risk BCR)
Presented by:
David Morris, MD, FACS
Urology Associates, P.C., Nashville, TN
Nashville, TN
RSVP:
To RSVP, please scan the QR code, visit https://astellas.virtualspeakercast.net/1402,
or contact Theresa Hindle at (530) 340-1662 or theresa.hindle@astellas.com
by Monday, November 4, 2024